[go: up one dir, main page]

CL2016001809A1 - Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15). - Google Patents

Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).

Info

Publication number
CL2016001809A1
CL2016001809A1 CL2016001809A CL2016001809A CL2016001809A1 CL 2016001809 A1 CL2016001809 A1 CL 2016001809A1 CL 2016001809 A CL2016001809 A CL 2016001809A CL 2016001809 A CL2016001809 A CL 2016001809A CL 2016001809 A1 CL2016001809 A1 CL 2016001809A1
Authority
CL
Chile
Prior art keywords
amino acid
receptor modulators
bile acids
acid conjugates
hydroxyl derivatives
Prior art date
Application number
CL2016001809A
Other languages
English (en)
Inventor
Roberto Pelliciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CL2016001809A1 publication Critical patent/CL2016001809A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPUESTOS DERIVADOS DE 11-HIDROXILO DE ACIDOS BILIARES Y CONJUGADOS DE AMINOACIDOS DE LOS MISMOS, COMO MODULADORES DEL RECEPTOR DE FARNESOID X; CONJUNTO DE ELEMENTOS; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DE UNA ENFERMEDAD CARDIOVASCULAR, UNA ENFERMEDAD HEPATICA, UN TRASTORNO DE LIPIDOS, CANCER Y UNA ENFERMEDAD NEUROLOGICA, ENTRE OTRAS (DIVISIONAL SOL. N° 3344-15).
CL2016001809A 2013-05-14 2016-07-15 Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15). CL2016001809A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361823169P 2013-05-14 2013-05-14

Publications (1)

Publication Number Publication Date
CL2016001809A1 true CL2016001809A1 (es) 2017-01-27

Family

ID=50721801

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015003344A CL2015003344A1 (es) 2013-05-14 2015-11-13 Derivados 11-hidroxilo de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor de farnesoid x.
CL2016001809A CL2016001809A1 (es) 2013-05-14 2016-07-15 Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015003344A CL2015003344A1 (es) 2013-05-14 2015-11-13 Derivados 11-hidroxilo de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor de farnesoid x.

Country Status (37)

Country Link
US (7) US9611289B2 (es)
EP (4) EP3360882B1 (es)
JP (2) JP6326131B2 (es)
KR (1) KR102229952B1 (es)
CN (2) CN105377870B (es)
AU (1) AU2014267324B2 (es)
BR (1) BR112015028399B1 (es)
CA (1) CA2912139C (es)
CL (2) CL2015003344A1 (es)
CR (1) CR20150643A (es)
CY (1) CY1122614T1 (es)
DK (4) DK3360882T3 (es)
EA (1) EA030152B1 (es)
ES (4) ES2843737T3 (es)
GT (1) GT201500324A (es)
HR (1) HRP20180931T1 (es)
HU (1) HUE037996T2 (es)
IL (2) IL242555B (es)
LT (1) LT2997035T (es)
MA (1) MA38647B1 (es)
ME (1) ME03082B (es)
MX (1) MX352065B (es)
MY (1) MY187886A (es)
NI (1) NI201500160A (es)
PE (2) PE20160665A1 (es)
PH (1) PH12015502576B1 (es)
PL (3) PL3360882T3 (es)
PT (3) PT3360882T (es)
RS (1) RS57372B1 (es)
SA (1) SA515370140B1 (es)
SG (1) SG11201509352XA (es)
SI (3) SI3360881T1 (es)
SM (1) SMT201800326T1 (es)
TN (1) TN2015000497A1 (es)
TR (1) TR201809041T4 (es)
UA (1) UA118673C2 (es)
WO (1) WO2014184271A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2843737T3 (es) 2013-05-14 2021-07-20 Intercept Pharmaceuticals Inc Derivados sustituidos con 11-hidroxilo-6 de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores de receptor de farnesoide X
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
RS59910B1 (sr) * 2014-05-29 2020-03-31 Bar Pharmaceuticals S R L Derivati holana za upotrebu u lečenju i/ili prevenciji fxr i tgr5/gpbar1 posredovanih bolesti
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
EP3221334B1 (en) 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CA2968309A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
EP3253382B1 (en) 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
WO2016130809A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SG11201707328SA (en) * 2015-03-09 2017-10-30 Intercept Pharmaceuticals Inc Methods for modulating bone density
WO2016145216A1 (en) * 2015-03-10 2016-09-15 Metselex, Inc. Fluorinated and alkylated bile acids
EP3267991A4 (en) * 2015-03-13 2018-12-12 Salk Institute for Biological Studies Treating latent autoimmune diabetes of adults with farnesoid x receptor agonists to activate intestinal receptors
SG11201707263XA (en) * 2015-03-31 2017-10-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
WO2016168553A1 (en) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Deuterated obeticholic acid
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) * 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
JP6824966B2 (ja) * 2015-09-21 2021-02-03 インターセプト ファーマシューティカルズ， インコーポレイテッド 肝臓の再生を促進する方法
UA123948C2 (uk) * 2015-10-07 2021-06-30 Інтерсепт Фармасьютікалз, Інк. Модулятори фарнезоїдного х-рецептора
MY196292A (en) * 2016-01-28 2023-03-24 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid Derivative Fxr Agonist
WO2017147137A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
ES2874682T3 (es) * 2016-03-11 2021-11-05 Intercept Pharmaceuticals Inc Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
JP6968821B2 (ja) * 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
SG11201906987RA (en) 2017-02-21 2019-09-27 Genfit Combination of a ppar agonist with a fxr agonist
WO2018156916A2 (en) * 2017-02-23 2018-08-30 Intercept Pharmaceuticals, Inc Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
WO2018226724A1 (en) * 2017-06-05 2018-12-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of diabetic eye diseases with a bile acid derivatives
CA3067219A1 (en) * 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
EP3658150A4 (en) 2017-07-24 2021-03-31 Intercept Pharmaceuticals, Inc. Isotopically labeled gallic acid derivatives
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN109182451B (zh) * 2018-08-21 2021-06-11 四川大学 细胞色素cyp3a7酶的新型特异性探针反应及其应用
BR112021011762A2 (pt) 2019-01-15 2021-11-03 Gilead Sciences Inc Compostos para modulação de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
CA3142358A1 (en) * 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
CN110540955B (zh) * 2019-08-28 2021-09-17 北京协同创新研究院 一种提高分化细胞中nrob2基因表达量的方法
CA3159163A1 (en) 2020-01-15 2021-07-22 Raphael Darteil Use of fxr agonists for treating an infection by hepatitis d virus
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2022233398A1 (en) * 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
WO2025059651A1 (en) * 2023-09-14 2025-03-20 The Regents Of The University Of California Bile salt modification to prevent and treat enteric disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080775A (en) * 1934-08-22 1937-05-18 Celanese Corp Shedding mechanism for circular looms
US2802775A (en) * 1953-05-29 1957-08-13 Merck & Co Inc 11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) * 1983-05-09 1984-11-20 Kuraray Co Ltd １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
ITMI20021532A1 (it) * 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP1734970B1 (en) * 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ES2523591T3 (es) * 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
ES2843737T3 (es) 2013-05-14 2021-07-20 Intercept Pharmaceuticals Inc Derivados sustituidos con 11-hidroxilo-6 de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores de receptor de farnesoide X

Also Published As

Publication number Publication date
EA030152B1 (ru) 2018-06-29
IL272718B (en) 2020-11-30
PL2997035T3 (pl) 2018-10-31
BR112015028399A2 (pt) 2017-07-25
US20210228599A1 (en) 2021-07-29
PE20200844A1 (es) 2020-08-18
WO2014184271A1 (en) 2014-11-20
US9611289B2 (en) 2017-04-04
KR102229952B1 (ko) 2021-03-22
ES2671427T3 (es) 2018-06-06
DK3360881T3 (da) 2021-03-15
AU2014267324A1 (en) 2015-11-26
DK2997035T3 (en) 2018-07-02
SI3360882T1 (sl) 2021-06-30
PT2997035T (pt) 2018-07-18
CL2015003344A1 (es) 2016-07-15
PT3360881T (pt) 2021-02-19
US20170216316A1 (en) 2017-08-03
DK3848038T3 (da) 2023-02-06
EP3848038A1 (en) 2021-07-14
ES2936638T3 (es) 2023-03-21
CR20150643A (es) 2016-06-01
CY1122614T1 (el) 2020-07-31
PL3360881T3 (pl) 2021-11-15
US20140371190A1 (en) 2014-12-18
AU2014267324B2 (en) 2017-11-02
ES2843737T3 (es) 2021-07-20
SI2997035T1 (sl) 2018-10-30
EP2997035B8 (en) 2018-05-23
MA38647B1 (fr) 2019-05-31
CN108245523B (zh) 2021-03-26
US20240398834A1 (en) 2024-12-05
SI3360881T1 (sl) 2021-06-30
KR20160007586A (ko) 2016-01-20
CN105377870B (zh) 2018-04-03
US20230233581A1 (en) 2023-07-27
MY187886A (en) 2021-10-26
RS57372B1 (sr) 2018-08-31
MX352065B (es) 2017-11-08
PH12015502576B1 (en) 2018-09-12
TN2015000497A1 (en) 2017-04-06
SA515370140B1 (ar) 2017-04-11
EP2997035A1 (en) 2016-03-23
EP3360881B1 (en) 2020-12-09
US20190209586A1 (en) 2019-07-11
NI201500160A (es) 2016-01-04
ME03082B (me) 2019-01-20
EP3360882A1 (en) 2018-08-15
PL3360882T3 (pl) 2021-10-25
ES2847002T3 (es) 2021-07-30
GT201500324A (es) 2017-09-28
EA201592055A1 (ru) 2016-11-30
IL242555A0 (en) 2016-02-01
UA118673C2 (uk) 2019-02-25
NZ714082A (en) 2021-02-26
JP6326131B2 (ja) 2018-05-16
EP3360881A1 (en) 2018-08-15
SG11201509352XA (en) 2015-12-30
HK1221471A1 (zh) 2017-06-02
IL272718A (en) 2020-04-30
EP3848038B1 (en) 2022-11-09
JP2016518429A (ja) 2016-06-23
IL242555B (en) 2020-04-30
EP2997035B1 (en) 2018-03-28
PT3360882T (pt) 2021-02-12
LT2997035T (lt) 2018-08-10
US11000532B2 (en) 2021-05-11
US20200297739A1 (en) 2020-09-24
CA2912139C (en) 2021-04-20
DK3360882T3 (da) 2021-03-08
CA2912139A1 (en) 2014-11-20
HUE037996T2 (hu) 2018-09-28
SMT201800326T1 (it) 2018-07-17
HK1253326A1 (zh) 2019-06-14
PH12015502576A1 (en) 2016-02-29
HRP20180931T1 (hr) 2018-10-05
BR112015028399B1 (pt) 2021-11-16
US10532061B2 (en) 2020-01-14
CN108245523A (zh) 2018-07-06
TR201809041T4 (tr) 2018-07-23
PE20160665A1 (es) 2016-08-07
EP3360882B1 (en) 2020-12-09
CN105377870A (zh) 2016-03-02
JP2018127481A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MX378315B (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos
CL2018000883A1 (es) Moduladores del receptor x farnesoide
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2012001352A1 (es) Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras.